51
Participants
Start Date
February 6, 2018
Primary Completion Date
June 30, 2023
Study Completion Date
August 13, 2025
Olaparib
Give PO
Ramucirumab
Given IV
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
University of Florida Health Science Center - Gainesville, Gainesville
Vanderbilt Breast Center at One Hundred Oaks, Nashville
Vanderbilt University/Ingram Cancer Center, Nashville
Wayne State University/Karmanos Cancer Institute, Detroit
Weisberg Cancer Treatment Center, Farmington Hills
University of Wisconsin Carbone Cancer Center - University Hospital, Madison
M D Anderson Cancer Center, Houston
City of Hope Comprehensive Cancer Center, Duarte
City of Hope South Pasadena, South Pasadena
City of Hope Upland, Upland
City of Hope Corona, Corona
City of Hope Antelope Valley, Lancaster
UCSF Medical Center-Mount Zion, San Francisco
University of California Davis Comprehensive Cancer Center, Sacramento
Smilow Cancer Hospital-Derby Care Center, Derby
Smilow Cancer Hospital Care Center-Fairfield, Fairfield
Smilow Cancer Hospital Care Center - Guilford, Guilford
Smilow Cancer Hospital Care Center at Saint Francis, Hartford
Smilow Cancer Center/Yale-New Haven Hospital, New Haven
Yale University, New Haven
Yale-New Haven Hospital North Haven Medical Center, North Haven
Smilow Cancer Hospital-Orange Care Center, Orange
Smilow Cancer Hospital-Torrington Care Center, Torrington
Smilow Cancer Hospital Care Center-Trumbull, Trumbull
Smilow Cancer Hospital-Waterbury Care Center, Waterbury
Smilow Cancer Hospital Care Center - Waterford, Waterford
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick
Rutgers Cancer Institute of New Jersey, New Brunswick
National Cancer Institute (NCI)
NIH